Our study integrated NSC48160 with the SLC7A11 inhibitor HG106 as a therapeutic intervention for HCC, indicating that this combination yields a significant inhibitory effect (Figure 5). The gene discussed is SLC7A11; the disease is hepatocellular carcinoma.